AMDA vs. MOTS, SINT, BJDX, OSAP, OSA, RSLS, NMRD, DYNT, BTTX, and BLPH
Should you be buying Amedica stock or one of its competitors? The main competitors of Amedica include Motus GI (MOTS), Sintx Technologies (SINT), Bluejay Diagnostics (BJDX), ProSomnus (OSAP), ProSomnus (OSA), ReShape Lifesciences (RSLS), Nemaura Medical (NMRD), Dynatronics (DYNT), Better Therapeutics (BTTX), and Bellerophon Therapeutics (BLPH). These companies are all part of the "medical" sector.
Motus GI (NASDAQ:MOTS) and Amedica (NASDAQ:AMDA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, community ranking, dividends, media sentiment, institutional ownership and valuation.
Motus GI has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Amedica has a beta of -1.24, suggesting that its share price is 224% less volatile than the S&P 500.
Amedica has higher revenue and earnings than Motus GI. Amedica is trading at a lower price-to-earnings ratio than Motus GI, indicating that it is currently the more affordable of the two stocks.
Amedica received 144 more outperform votes than Motus GI when rated by MarketBeat users. However, 65.73% of users gave Motus GI an outperform vote while only 64.90% of users gave Amedica an outperform vote.
20.1% of Motus GI shares are held by institutional investors. Comparatively, 3.7% of Amedica shares are held by institutional investors. 1.6% of Motus GI shares are held by company insiders. Comparatively, 0.9% of Amedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Motus GI currently has a consensus price target of $28.88, suggesting a potential upside of 40,004.17%. Given Amedica's higher probable upside, research analysts plainly believe Motus GI is more favorable than Amedica.
Amedica has a net margin of -139.62% compared to Amedica's net margin of -4,033.54%. Amedica's return on equity of 0.00% beat Motus GI's return on equity.
In the previous week, Amedica's average media sentiment score of 0.00 equaled Motus GI'saverage media sentiment score.
Summary
Motus GI beats Amedica on 9 of the 15 factors compared between the two stocks.
Get Amedica News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
